Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

521 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors.
Mateo J, Berlin J, de Bono JS, Cohen RB, Keedy V, Mugundu G, Zhang L, Abbattista A, Davis C, Gallo Stampino C, Borghaei H. Mateo J, et al. Among authors: de bono js. Cancer Chemother Pharmacol. 2014 Nov;74(5):1039-46. doi: 10.1007/s00280-014-2576-8. Epub 2014 Sep 12. Cancer Chemother Pharmacol. 2014. PMID: 25212537 Free PMC article. Clinical Trial.
A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours.
Greystoke A, Blagden S, Thomas AL, Scott E, Attard G, Molife R, Vidal L, Pacey S, Sarkar D, Jenner A, De-Bono JS, Steward W. Greystoke A, et al. Among authors: de bono js. Ann Oncol. 2006 Aug;17(8):1313-9. doi: 10.1093/annonc/mdl097. Epub 2006 May 25. Ann Oncol. 2006. PMID: 16728482 Free article. Clinical Trial.
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days.
Benson C, White J, De Bono J, O'Donnell A, Raynaud F, Cruickshank C, McGrath H, Walton M, Workman P, Kaye S, Cassidy J, Gianella-Borradori A, Judson I, Twelves C. Benson C, et al. Br J Cancer. 2007 Jan 15;96(1):29-37. doi: 10.1038/sj.bjc.6603509. Epub 2006 Dec 19. Br J Cancer. 2007. PMID: 17179992 Free PMC article. Clinical Trial.
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours.
Blagden SP, Molife LR, Seebaran A, Payne M, Reid AH, Protheroe AS, Vasist LS, Williams DD, Bowen C, Kathman SJ, Hodge JP, Dar MM, de Bono JS, Middleton MR. Blagden SP, et al. Among authors: de bono js. Br J Cancer. 2008 Mar 11;98(5):894-9. doi: 10.1038/sj.bjc.6604264. Epub 2008 Mar 4. Br J Cancer. 2008. PMID: 18319713 Free PMC article. Clinical Trial.
A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours.
Scott EN, Thomas AL, Molife LR, Ahmed S, Blagden S, Fong PC, Kowal K, McCoy C, Wiesinger H, Steward W, De Bono J. Scott EN, et al. Cancer Chemother Pharmacol. 2009 Jul;64(2):425-9. doi: 10.1007/s00280-009-0968-y. Epub 2009 Mar 12. Cancer Chemother Pharmacol. 2009. PMID: 19280191 Free article. Clinical Trial.
521 results